Clinical Evaluation of IMPY SPECT for Diagnosis of Alzheimer's

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$500,000.00
Award Year:
2007
Program:
STTR
Phase:
Phase I
Contract:
1R41AG030241-01
Award Id:
85241
Agency Tracking Number:
AG030241
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
AVID RADIOPHARMACEUTICALS, INC., 3624 Market Street, 5th Floor, Philadelphia, PA, 19104
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
170631720
Principal Investigator:
DANIELSKOVRONSKY
(484) 716-0886
SKOVRONSKY@AVIDRP.COM
Business Contact:
DANIELSKOVRONSKY
() -
skovronsky@avidrp.com
Research Institute:
UNIVERSITY OF CALIFORNIA, SAN

UNIVERSITY OF CALIFORNIA SAN FRANCISCO
3333 California St., Ste 315
SAN FRANCISCO, CA, 94143

Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is the most common cause of dementia in the elderly, with more than 4.5 million Americans currently suffering from the disease. Clinical management of AD is complicated by lack of effective met hods for early and accurate diagnosis of the disease. Thus, there is a significant unmet need for Alzheimer's disease diagnostic tools. The hypothesis of this project is that single photon emission computed tomography (SPECT) imaging with 123 I-IMPY provid es a biomarker for detection of amyloid plaques useful for both 1) Early and definitive diagnosis of AD in the community setting and for 2) Evaluating new therapies targeted and reducing plaque burden in large multi-site clinical trials. To test this hypot hesis, a novel 123 I -labeled radiopharmaceutical, 123 I-IMPY, was developed to specifically and sensitively bind Aa (the chief constituent of amyloid plaques). Working with our collaborators, we have recently demonstrated the safety and biodistribution of this radiopharmaceutical in an initial Phase I clinical trial. In other ongoing clinical trials we are beginning to demonstrate the efficacy of this diagnostic imaging agent, however additional validation work as described in this grant is still required. Thus Phase I of this project will now assess the feasibility and reliability of using this radiopharmaceutical as a biomarker for measuring plaque burden in AD patients. If 123 I-IMPY has suitable clinical properties as a biomarker for measuring amyloid p laques then Phase II will test the characteristics of the biomarker in longitudinal studies of AD and mild cognitive impairment (MCI) patients. Successful accomplishment of these studies will yield an innovative radiopharmaceutical product for the evaluati on and diagnosis of AD. A widely available SPECT imaging test for AD will yield significant scientific, commercial and societal benefits. RELEVANCE Successful accomplishment of this Phase I project will result in the validation of 123 I-IMPY as an imaging biomarker for amyloid plaques in AD. Development of such a product will represent a significant technological and scientific innovation that will allow for widespread clinical benefits by facilitating early and accurate diagnosis of AD, using a technique ( SPECT imaging) appropriate for the primary care / community medical setting. In addition, it will allow for scientific and technological benefits by improving our understanding of AD and catalyzing the development and evaluation of novel therapies for this devastating disease.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government